P. Harris

发表

Anti-IL-6 Versus Anti-IL-6R Blocking Antibodies to Treat Acute Ebola Infection in BALB/c Mice: Potential Implications for Treating Cytokine Release Syndrome

R. Carback, T. Brasel, C. Herst, 2020, bioRxiv.

A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques

R. Carback, S. Ciotlos, T. Brasel, 2021, bioRxiv.

Paired SARS-CoV-2 spike protein mutations observed during ongoing SARS-CoV-2 viral transfer from humans to minks and back to humans

S. Pokhrel, R. Carback, S. Ciotlos, 2020, bioRxiv.

Survivin (BIRC5) peptide vaccine in the 4T1 murine mammary tumor model: a potential neoadjuvant T-cell immunotherapy for triple negative breast cancer

R. Carback, C. Herst, R. Rubsamen, 2023, bioRxiv.

Title: T-cell targeted immunotherapy against the tumor associated antigen survivin (BIRC5) as a potential neoadjuvant immunotherapy for triple negative breast cancer.

R. Carback, C. Herst, R. Rubsamen, 2022 .

An Approach for a Synthetic CTL Vaccine Design against Zika Flavivirus Using Class I and Class II Epitopes Identified by Computer Modeling

S. Ciotlos, E. Cunha-Neto, C. Herst, 2017, Front. Immunol..

anti-IL-6 versus anti-IL-6R Blocking Antibodies to Treat Acute Ebola Infection in BALB/c Mice with Potential Implications for Treating Patients Presenting with COVID-19

R. Carback, T. Brasel, C. Herst, 2020 .

Analysis of well-annotated next-generation sequencing data reveals increasing cases of SARS-CoV-2 reinfection with Omicron

R. Carback, M. Rubsamen, D. Mochly‐Rosen, 2023, Communications Biology.

Increasing Cases of SARS-CoV-2 Omicron Reinfection Reveals Ineffective Post-COVID-19 Immunity in Denmark and Conveys the Need for Continued Next-Generation Sequencing

R. Carback, M. Rubsamen, D. Mochly‐Rosen, 2022, medRxiv.

Survivin Expression in Luminal Breast Cancer and Adjacent Normal Tissue for Immuno-Oncology Applications

R. Carback, C. Herst, P. Harris, 2023, International journal of molecular sciences.

An effective CTL peptide vaccine for Ebola Zaire Based on Survivors’ CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design

J Sidney, J. Sidney, A. Sette, 2020, bioRxiv.

Survivin (BIRC5) Peptide Vaccine in the 4T1 Murine Mammary Tumor Model: A Potential Neoadjuvant T Cell Immunotherapy for Triple Negative Breast Cancer: A Preliminary Study

R. Carback, C. Herst, R. Rubsamen, 2023, Vaccines.

New Vaccine Therapy for Triple-Negative Breast Cancer

P. Harris, Reid M Rubsamen, 2024, Current Breast Cancer Reports.

Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine

C. Herst, S. Burkholz, P. Harris, 2024, Vaccines.